Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into 2025 All-stock merger of equals transaction with Ceapro, Inc. expected to close in the second quarter of 2024 TORONTO, ONTARIO, March 27, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the... Read More

TORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“ Ceapro ”) are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals transaction (the “ Transaction ”) at their respective special meetings held today. The specific voting results were as... Read More

Aeterna Zentaris Board recommends shareholders vote FOR all resolutions, to create a diversified biopharmaceutical company with a compelling value proposition More information and materials available at www.AEZSmerger.com Shareholders with questions or who require assistance voting their shares should contact Kingsdale Advisors at 1-866-581-1513 (North American Toll Free) or 416-623-2513 (outside North America – text and... Read More

TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“ Ceapro ”), two innovative biopharmaceutical development companies, today announced that they have entered into a definitive agreement to combine operations in an all-stock merger of equals transaction (the “ Transaction ”). The combined company is expected to be... Read More

Launch of Ghryvelin ™ in a number of key countries in the European Economic Area Approval of Macrilen ® in South Korea in September Ended the quarter with $38.8 million in cash, expected to fund operations and advancement of priority pipeline programs into 2025 TORONTO, ONTARIO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical... Read More

Live moderated webcast with Klaus Paulini, Chief Executive Officer of Aeterna Zentaris on Wednesday, October 25 th at 10:00 AM ET TORONTO, ONTARIO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus... Read More

TORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the H.C. Wainwright 25th Annual Global Investment Conference being... Read More

Ended the quarter with $42.2 million in cash, expected to fund operations into 2025 Driving patient recruitment for Phase 3 DETECT trial for the diagnosis of Childhood Onset Growth Hormone Deficiency TORONTO, ONTARIO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of... Read More

Highlights progress, recent developments and upcoming key milestones Company continues to build growing body of data across pipeline, advancing towards first in human studies Strong financial position with cash projected to fund operations and advancement of priority pipeline programs into 2025 TORONTO, ONTARIO, July 13, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a... Read More

Live moderated video webcast on Thursday, July 13 th at 10:00 AM ET TORONTO, ONTARIO, July 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer and Eckhard Guenther, PhD,... Read More

TORONTO, ONTARIO, June 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that all items of business were approved at its virtual Annual General and Special Meeting of Shareholders (the "AGM") held today. Results of the... Read More

TORONTO, ONTARIO, May 15, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that its Virtual Annual General and Special Meeting of Shareholders (the “AGM”) will be held on June 14, 2023, at 10:00 a.m. (ET). The platform... Read More

Ended the quarter with $46.6 million in cash, expected to fund operations into 2025 Continued efforts to accelerate recruitment for DETECT trial Actively seeking alternate development and commercialization partners for Macrilen ® (macimorelin) in the U.S. and other territories not currently partnered TORONTO, ONTARIO, May 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the... Read More

U.S. sales of Macrilen ® for adult use to be temporarily discontinued as of May 23, 2023, while DETECT trial continues in order to expand the opportunity for pediatric usage of Macrilen ® Sales and commercialization efforts continue to move forward in European Economic Area and UK under recent agreement with Pharmanovia United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for Aeterna’s U.S.... Read More

Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025 Executing strategy to streamline advancement of development programs, build upon growing body of data across pipeline, and progress towards go/no-go decision milestones Ongoing efforts to accelerate recruitment for our DETECT trial and establish partnering rights to Macrilen ™ in the U.S. and Canada TORONTO, ONTARIO,... Read More

Pharmanovia to acquire license to GHRYVELIN ™ from Aeterna Zentaris’ existing licensee, Consilient Health, effective immediately TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that... Read More

Aeterna Zentaris focused on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen™ in the U.S. and Canada Company continues to build growing body of data across its development pipeline, advancing towards go/no-go decision milestones at each stage to establish prioritization and drive momentum Strategic decision to streamline development programs by discontinuing the Company’s... Read More

Live video webcast on Thursday, January 19 th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at... Read More